<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">Liver metastases</z:e> occur in up to 60% of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and the control of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> is considered to be of primary importance because it is a critical factor in determining prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Radiofrequency ablation (RFA) therapy is one of the least invasive techniques for unresectable hepatic <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and can be performed safely using percutaneous, laparoscopic, or open surgical techniques </plain></SENT>
<SENT sid="2" pm="."><plain>The local <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> rates after RFA for colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> range from 8.8% to 40.0%, and 5-year survival rates range from 20.0% to 48.5% </plain></SENT>
<SENT sid="3" pm="."><plain>No prospective, randomized trials comparing the efficacy of RFA with that of surgical resection for colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> are currently available </plain></SENT>
<SENT sid="4" pm="."><plain>However, some retrospective studies have reported that patients who received RFA had a survival rate similar to that observed in surgically treated groups, while other studies have reported better survival among patients who underwent surgical resection </plain></SENT>
<SENT sid="5" pm="."><plain>The use of a laparoscopic or open surgical approach allows the repeated placement of RFA electrodes at multiple sites to ablate larger <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>An accurate evaluation of treatment response is very important for the success of RFA therapy because a sufficient safety margin (at least 0.5 cm) can prevent local <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>This review critically summarizes the current status of RFA for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>